Dianthus Therapeutics DNTH Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's retained earnings?
- Dianthus Therapeutics (DNTH) reported retained earnings of -$377.56M in Q1 2026.
- How has Dianthus Therapeutics's retained earnings changed year-over-year?
- Dianthus Therapeutics's retained earnings decreased by 85.2% year-over-year, from -$203.9M to -$377.56M.
- What is the long-term trend for Dianthus Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's retained earnings has grown at a 5.8% compound annual growth rate (CAGR), from -$254.43M to -$336.73M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.